Article
The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.
PLoS pathogens - 1 Jan 2013
Tavis John E, Cheng Xiaohong, Hu Yuan, Totten Michael, Cao Feng, Michailidis Eleftherios, Aurora Rajeev, Meyers Marvin J, Jacobsen E Jon, Parniak Michael A, Sarafianos Stefan G
Abstract excerpt
Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects. The profound suppression of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of extinction. Consequently, more patients...
Topics
- Antiviral Agents
- Drug Design
- Drug Evaluation, Preclinical
- Genotype
- HIV Integrase Inhibitors
- Hepatitis B virus
- Humans
- In Vitro Techniques
- Molecular Targeted Therapy
- Recombinant Proteins
- Ribonuclease H, Human Immunodeficiency Virus
- Viral Load